ProfileGDS5678 / 1441238_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 72% 71% 71% 69% 70% 77% 73% 73% 71% 71% 71% 72% 71% 71% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 14.5389272
GSM967853U87-EV human glioblastoma xenograft - Control 24.4688771
GSM967854U87-EV human glioblastoma xenograft - Control 34.4706171
GSM967855U87-EV human glioblastoma xenograft - Control 44.3481469
GSM967856U87-EV human glioblastoma xenograft - Control 54.3894370
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 15.082677
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 24.609773
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 34.6996273
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 44.4426571
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 14.4711871
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 24.4600171
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 34.5879672
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 44.4832271
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 54.4732571